According to data from the analysis of antibody levels, of the 1905 people vaccinated and monitored in the study carried out by Instituto Gulbenkian de Ciência, those who followed a mixed vaccination scheme, with the first dose of Oxford/AstraZeneca and the second dose of Pfizer/BioNTech, generated a greater number of antibodies compared to the two doses of Oxford/AstraZeneca vaccine. The data also revealed that the levels of antibodies, after the two doses of the Pfizer/BioNTech vaccine, were higher than those generated with other vaccination schemes.

Check the latest news in the press about the study (in Portuguese):

in Expresso

in RTP